An expanding appreciation of the role chemokine receptors play in cancer progression

Current Pharmaceutical Design

Volumn 10, Issue 19, 2004, Pages 2377-2389

  Howard, O M Zack ^a   Galligan, Carole L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CYTOKINE ANTIBODY; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECOMBINANT CYTOKINE; STROMAL CELL DERIVED FACTOR 1ALPHA; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; LIGAND BINDING; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

CELL SURVIVAL; CHEMOKINES; DISEASE PROGRESSION; HUMANS; LIGANDS; NEOPLASMS; PEPTIDES; RECEPTORS, CHEMOKINE;

EID: 3042820624     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383935     Document Type: Review

References (140)

1. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol 1987; 139: 788-93.
2. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987; 84: 9233-7.
3. Sica A, Matsushima K, Van Damme J, Wang JM, Polentarutti N, Dejana E, et al. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology 1990; 69: 548-53.
4. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-7.
5. Ono SJ, Nakamura T, Miyazaki D, Olibayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003; 111: 1185-99.
6. Muller G, Reiterer P, Hopken UE, Golfier S, Lipp M. Role of homeostatic chemokine and sphingosine-1-phosphate receptors in the organization of lymphoid tissue. Ann N Y Acad Sci 2003; 987: 107-16.
7. Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci 2002; 23: 459-67.
8. Locati M, Otero K, Schioppa T, Signorelli P, Perrier P, Baviera S, et al. The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy 2002; 57: 972-82.
9. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-76.
10. Curnock AP, Logan MK, Ward SG. Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 2002; 105: 125-36.
11. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravelti JL, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003; 63: 1969-74.
12. Werle M, Schmal U, Hanna K, Kreuzer J. MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res 2002; 56: 284-92.
13. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002; 277: 49481-7.
14. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002; 99: 2703-11.
15. Mirshahi F, Pourtau J, Li H, Moraine M, Trochon V, Legrand E, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000; 99: 587-94.
16. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003; 10: 359-70.
17. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-76.
18. Finke D, Acha-Orbea H, Mattis A, Lipp M, Kraehenbuhl J. CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5. Immunity 2002, 17: 363-73.
19. D'Ambrosio D, Albanesi C, Lang R, Girolomoni G, Sinigaglia F, Laudanna C. Quantitative differences in chemokine receptor engagement generate diversity in integrin-dependent lymphocyte adhesion. J Immunol 2002; 169: 2303-12.
20. Van Den Steen PE, Wuyts A, Husson SJ, Proust P, Van Damme J, Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003; 270: 3739-49.
21. Cascieri MA, Springer MS. The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curr Opin Chem Biol 2000; 4: 420-7.
22. Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr Opin Chem Biol 2002; 6: 510-25.
23. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 2003; 22: 765-71.
24. Maheshwari A, Lu W, Lacson A, Barleycorn AA, Nolan S, Christensen RD, et al. Effects of interleukin-8 on the developing human intestine. Cytokine 2002; 20: 256-67.
25. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N. Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 2000; 6: 2735-40.
26. Mockenhaupt M, Peters F, Schwenk-Davoine I, Herouy Y, Schraufstatter I, Elsner P, et al. Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes. Int J Mol Med 2003; 12: 597-601.
27. Ramjeesingh R, Leung R, Siu CH. Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J 2003; 17: 1292-4.
28. Metzner B, Hofmann C, Heinemann C, Zimpfer U, Schraufstatter I, Schopf E, et al. Overexpression of CXC-chemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB and A431. Oncol Rep 1999; 6: 1405-10.
29. Tecimer T, Dlott J, Chuntharapai A, Martin AW, Peiper SC. Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells. Arch Pathol Lab Med 2000; 124: 520-5.
30. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001; 7: 3299-304.
31. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001; 3: 33-42.
32. Reiland J, Furcht LT, McCarthy JB. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999; 41: 78-88.
33. Ferrer FA, Pantschenko AG, Miller LJ, Anderson K, Grunnet M, McKenna PH, et al. Angiogenesis and neuroblastomas: interleukin-8 and interleukin-8 receptor expression in human neuroblastoma. J Urol 2000; 164: 1016-20.
34. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-49.
35. Lu D, Duvic M, Medeiros LJ, Luthra R, Dorfman DM, Jones D. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol 2001; 115: 413-21.
36. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002; 43: 461-6.
37. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95: 627-32.
38. Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999; 104: 115-21.
39. Schweyer S, Soruri A, Baumhoer D, Peters J, Cattaruzza M, Radzun HJ, et al. Expression of CXC chemokine IP-10 in testicular germ cell tumours. J Pathol 2002; 197: 89-97.
40. Oh JW, Drabik K, Kutsch O, Choi C, Tousson A, Benveniste EN. CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 2001; 166: 2695-704.
41. Barbero S, Bajetto A, Bonavia R, Porcile C, Piccioli P, Pirani P, et al. Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann N Y Acad Sci 2002; 973: 60-9.
42. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294-300.
43. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003; 5: 31-6.
44. Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003; 5: R144-50.
45. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002; 100: 2597-606.
46. Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, Kim H, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003; 88: 408-16.
47. Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of routine B16 melanoma cells, Cancer Res 2002; 62: 7328-34.
48. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Stricter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167: 1676-86.
49. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-57.
50. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-8.
51. Milliken D, Scotton C, Raju S, Balkwill F. Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002; 8: 1108-14.
52. Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001; 15: 752-6.
53. Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol 2002; 119: 492-5.
54. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203-10.
55. Lu P, Nakamoto Y, Nemoto-Sasaki Y, Fujii C, Wang H, Hashii M, et al. Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. Am J Pathol 2003; 162: 1249-58.
56. Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer 2001; 85: 891-7.
57. Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003; 122: 39-52.
58. Brock IV, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003; 88: 855-62.
59. Cignetti A, Vallario A, Roato I, Circosta P, Strola G, Scielzo C, et al. The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Exp Hematol 2003; 31: 495-503.
60. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-4.
61. Kleinhans M, Tun-Kyi A, Gilliet M, Kadin ME, Dummer R, Burg G, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 2003; 101: 1487-93.
62. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002; 119: 1405-10.
63. Dellacasagrande J, Schreurs OJ, Hofgaard PO, Omholt H, Steinsvoll S, Schenck K, et al. Liver metastasis of cancer facilitated by chemokine receptor CCR6. Scand J Immunol 2003; 57: 534-44.
64. Rodig SJ, Jones D, Shahsafaei A, Dorfman DM. CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Hum Pathol 2002; 33: 1227-33.
65. Nakayama T, Fujisawa R, Izawa D, Hieshima K, Takada K, Yoshie O. Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCR4 and CXCR5. J Virol 2002; 76: 3072-7.
66. Hopken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002; 99: 1109-16.
67. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
68. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 2003; 105: 186-9.
69. Hasegawa H, Nomura T, Kohno M, Tateishi N, Suzuki Y, Maeda N, et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 2000; 95: 30-8.
70. Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 3406-12.
71. Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, et al. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001; 158: 867-77.
72. Lentsch AB. The Duffy antigen/receptor for chemokines [DARC] and prostate cancer. A role as clear as black and white? FASEB J 2002; 16[9]: 1093-5.
73. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237: 474-82.
74. Lillie EO, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003; 5: 164-73.
75. Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 2003; 5: 140-6.
76. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
77. Neumark E, Anavi R, Witz IP, Ben-Baruch A. MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunol Lett 1999; 68: 141-6.
78. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62: 1093-102.
79. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001; 7: 285-9.
80. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A. Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer 1993; 55: 926-30.
81. Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, Murphy WJ. Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin Cancer Res 2002; 8: 2655-65.
82. Borgstrom P, Discipio R, Maione TE. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res 1998; 18: 4035-41.
83. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154: 1125-35.
84. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-6.
85. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 2003; 106: 879-86.
86. Wigler N, Shina S, Kaplan O, Luboshits G, Chaitchik S, Keydar I, et al. Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease. Isr Med Assoc J 2002; 4: 940-3.
87. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997; 71: 257-66.
88. Bataille V. Genetic epidemiology of melanoma. Eur J Cancer 2003; 39: 1341-7.
89. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003; 3: 559-70.
90. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003; 22: 3180-7.
91. Balentien E, Han JH, Thomas HG, Wen DZ, Samantha AK, Zachariae CO, et al. Recombinant expression, biochemical characterization, and biological activities of the human MGSA/gro protein. Biochemistry 1990; 29: 10225-33.
92. Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 1995; 55: 2470-5.
93. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18.
94. Gutman M, Even-Sapir E, Merimsky O, Trejo L, Klausner JM, Lev-Chelouche D. The role of interleukin-8 in the initiation and progression of human cutaneous melanoma. Anticancer Res 2002; 22: 3395-8.
95. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118: 915-22.
96. Moore BB, Arenberg DA, Addison CL, Keane MP, Stricter RM. Tumor angiogenesis is regulated by CXC chemokines. J Lab Clin Med 1998; 132: 97-103.
97. Westphal JR, Van't Hullenaar R, Peek R, Willems RW, Crickard K, Crickard U, et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000; 86: 768-76.
98. Grainger DJ, Reckless J. Broad-spectrum chemokine inhibitors [BSCIs] and their anti-inflammatory effects in vivo. Biochem Pharmacol 2003; 65: 1027-34.
99. Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 2001; 115: 554-62.
100. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 [ABX-IL8] inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161: 125-34.
101. Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000; 198: 83-95.
102. Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, et al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 2001; 16: 106-19.
103. Qiu B, Stefanos S, Ma J, Lalloo A, Perry BA, Leibowitz MJ, et al. A hydrogel prepared by in situ cross-linking of a thiol-containing polyethylene glycol-based copolymer: a new biomaterial for protein drug delivery. Biomaterials 2003; 24: 11-8.
104. Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, et al. A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol 1998; 161: 3729-36.
105. Li J, Flu P, Khawli LA, Epstein AL. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother 2003; 26: 320-31.
106. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2: 175-84.
107. Belman N, Bonnem EM, Harvey HA, Lipton A. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs 1996; 14: 387-9.
108. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184: 981-92.
109. Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM. Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunol Immunother 2001; 50: 533-8.
110. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
111. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276: 43503-8.
112. Opdenakker G, Van Damme J. Chemokines and proteinases in autoimmune diseases and cancer. Verb K Acad Genceskd Belg 2002; 64: 105-36.
113. Crump MP, Spyracopoulos L, Lavigne P, Kim KS, Clark-lewis I, Sykes BD. Backbone dynamics of the human CC chemokine eotaxin: fast motions, slow motions, and implications for receptor binding. Protein Sci 1999; 8: 2041-54.
114. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999; 94: 1899-905.
115. Menten P, Wuyts A, Van Damme J. Monocyte chemotactic protein-3. Eur Cytokine Netw 2001; 12: 554-60.
116. Appay V, Brown A, Cribbes S, Randle E, Czaplewski LG. Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants. J Biol Chem 1999; 274: 27505-12.
117. Czaplewski LG, McKeating J, Craven CJ, Higgins LD, Appay V, Brown A, et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem 1999; 274: 16077-84.
118. Fujisawa N, Hayashi S, Miller EJ. A synthetic peptide inhibitor for alpha-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice. Melanoma Res 1999; 9: 105-14.
119. Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE, et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 1999; 274: 32478-85.
120. Elsner J, Mack M, Bruhl H, Dulkys Y, Kimmig D, Simmons G, et al. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 2000; 275: 7787-94.
121. Bhatia M, Proudfoot AE, Wells TN, Christmas S, Neoptolemos JP, Slavin J. Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis. Br J Surg 2003; 90: 699-704.
122. Song E, Zou H, Yao Y, Proudfoot A, Antus B, Liu S, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002; 61: 676-85.
123. Bedke J, Stojanovic T, Grone HJ, Heuser M, Scheele L, Proudfoot AE, et al. Met-RANTFS improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant Proc 2002; 34: 1049.
124. Stojanovic T, Bedke J, Grone HJ, Proudfoot AE, Becker H, Markus P, et al. Met-RANTES inhibition of mucosal perfusion failure in acute intestinal transplant rejection - role of endothelial cell-leukocyte interaction. J Vasc Res 2002; 39: 51-8.
125. Anders HJ, Frink M, Linde Y, Banas B, Wornle M, Cohen CD, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003; 170: 5658-66.
126. He R, Tan L, Browning DD, Wang JM, Ye RD. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J Immunol 2000; 165: 4598-605.
127. Le Y, Yang Y, Cui Y, Yazawa H, Gong W, Qiu C, et al. Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol 2002; 2: 1-13.
128. Jaye DL, Edens HA, Mazzucchelli L, Parkos CA. Novel G protein-coupled responses in leukocytes elicited by a chemotactic bacteriophage displaying a cell type-selective binding peptide. J Immunol 2001; 166: 7250-9.
129. Marshall GR. Peptide interactions with G-protein coupled receptors. Biopolymers 2001; 60: 246-77.
130. Tarasova NI, Rice WG, Michejda CJ. Inhibition of G-protein-coupled receptor function by disruption of trans membrane domain interactions. J Biol Chem 1999; 274: 34911-5.
131. Chelli M, Alizon M. Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor. J Biol Chem 2001; 276: 46975-82.
132. Nicholas J. Human herpesvirus-8-encoded signalling ligands and receptors. J Biomed Sci 2003; 10: 475-89.
133. Zhou N, Luo Z, Luo J, Hall JW, Huang Z. A novel peptide antagonist of CXCR4 derived from the N-terininUS of viral chemokine vMIB-II. Biochemistry 2000; 39: 3782-7.
134. Sect BT, McFadden G. Viral chemokine-binding proteins. J Leukoc Biol 2002; 72: 24-34.
135. Casarosa P, Menge WM, Minisini R, Otto C, van Heteren J, Jongejan A, et al. Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J Biol Chem 2003; 278: 5172-8.
136. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253-8.
137. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-9.
138. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
139. Rajarathnam K. Designing decoys for chemokine-chemokine receptor interaction. Curr Pharm Design 2002; 8(24): 2159-69.
140. Saeki T, Naya A. CCR1 chemokine receptor antagonist. Curr Pharm Design 2003; 9(15): 1201-8.